Protein tyrosine kinase 6 (PTK6) degradation / disruption compounds and methods of use
Inventors
Jin, Jian • Irie, Hanna • Liu, Jing • Xiong, Yan • Byerly, Jessica • Tomita, Shannon • Hu, Jianping
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Disclosed herein are protein tyrosine kinase 6 (PTK6) degradation/disruption compounds including a PTK6 ligand, a degradation/disruption tag, and a linker, and methods of using such compounds in the treatment of FTK6-mediated diseases.
Core Innovation
The invention relates to PTK6-targeted bivalent heterobifunctional degraders/disruptors and a bivalent compound identified as YX39-105, defined by its chemical structure, together with pharmaceutically acceptable salts and enantiomers thereof. The compounds comprise a PTK6 ligand connected to a degradation/disruption tag through a linker, with related PTK6 ligand structures that can bind PTK6 or PTK6 mutants.
The degradation/disruption tags are defined with detailed chemical formulas and variable groups, and the linker moieties are defined by Formula 7 and related sub-formulas, including ring-containing linker options and diverse saturated, unsaturated, or heteroatom-containing groups. The tags are described as being capable of binding ubiquitin ligases, including cereblon, VHL, MDM2, TRIM21, TRIM24, KEAP1, and IAP, and as hydrophobic misfolding tags.
The disclosed material is largely structural disclosure centered on compound families and example compounds and analogs, including fluorinated aryl or heteroaromatic units, amide or urea-like linkages, and substituted bicyclic or heterocyclic moieties. The material also includes synthetic and characterization content for example compounds and linkers, together with PTK6 proteasomal poly-ubiquitination and degradation as the functional basis for PTK6 reduction.
Claims Coverage
The provided independent claim coverage is centered on one specific bivalent compound, YX39-105, defined by its chemical structure. The claim expressly includes pharmaceutically acceptable salts and enantiomers, and no further inventive features are stated in the provided material.
Bivalent compound YX39-105 defined by structure
A bivalent compound identified as YX39-105 having the following structure.
Pharmaceutically acceptable salts and enantiomers
The bivalent compound includes pharmaceutically acceptable salts and enantiomers thereof.
Overall, the claim coverage is limited to the structurally defined bivalent compound YX39-105, with explicit inclusion of pharmaceutically acceptable salts and enantiomers.
Stated Advantages
Removes kinase-dependent and kinase-independent PTK6 functions, including scaffolding function, as distinguished from kinase inhibition.
Reduces PTK6 protein levels.
Suppresses growth, invasion, and viability in 2D/3D cancer cell models.
Proteasome-dependent PTK6 degradation is supported by poly-ubiquitination and Western blot confirmation.
Documented Applications
Therapeutic treatment of PTK6-mediated diseases/cancers, including breast, ovarian, prostate, colon, pancreatic, bladder, liver, and cervical cancer, including relapsed or refractory cancer.
Use in 2D and 3D cancer cell models to assess PTK6 reduction, growth, invasion, and viability.
Use in in vivo studies including xenografts and a lung colonization metastasis assay.
Treating PTK6-mediated cancers by administration of PTK6 ligand-degradation/disruption tag conjugates with linkers.
Interested in licensing this patent?